source
- Eli Lilly fronts $2 billion for vaccine biotech deals as Infinimmune secures $75 million fundingEli Lilly announced it has paid $2 billion up front as part of its ongoing strategy to acquire vaccine‑focused biotechnology companies, a portion of a larger deal that could total up to $3.8 billio…
- Infinimmune secures $75 million Series A to develop longer-lasting eczema antibody therapiesInfinimmune, a biotech based in Alameda, California, announced on Tuesday that it has closed a $75 million Series A financing round. The capital will support the development of its first two clinic…